Cover Image
市場調查報告書

癌症的液態切片市場評估

Cancer Liquid Biopsy Market Assessment

出版商 Kalorama Information 商品編碼 580811
出版日期 內容資訊 英文 91 Pages
訂單完成後即時交付
價格
Back to Top
癌症的液態切片市場評估 Cancer Liquid Biopsy Market Assessment
出版日期: 2017年11月08日 內容資訊: 英文 91 Pages
簡介

本報告提供全球癌症液態切片市場相關調查分析,各種液態切片技術,開發的課題,競爭情形與市場趨勢,主要企業,及各癌症種類的市場概要與收益預測等系統性資訊。

第1章 摘要整理

第2章 液態切片技術

  • 簡介
  • 目前主要液態切片技術
  • 游離DNA
  • 液態切片的ctDNA的優點及缺點
  • 目前ctDNA型液態切片檢驗
  • 循環腫瘤細胞 (CTC) 液態切片
  • CTC型液態切片檢驗的開發的課題
  • CTC型液態切片實驗
  • 細胞外小胞以及其他的液態切片
  • 細胞外小胞型液態切片實驗

第3章 液態切片產業分析

  • 簡介
  • 競爭的等級
  • 競爭要素
  • 顯著的市場趨勢

第4章 癌症的液態切片市場分析

  • 整體液態切片市場概要
  • 液態切片市場前十大企業
  • 乳癌
  • 大腸癌
  • 肺癌
  • 卵巢癌
  • 前列腺癌
  • 其他癌症
目錄
Product Code: KLI15527193

Cancer Liquid Biopsy Market Assessment (Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer)

The term liquid biopsy encompasses various diagnostic methods that use liquid, non-tissue specimens to provide information that can aid in the diagnosis, treatment and monitoring of cancer. Currently, tissue biopsies, along with imaging techniques, are the standard methods used in the diagnosis of solid cancers, but despite their widespread use, they have many limitations that open the door for other diagnostic technologies in oncology clinical settings.

The Worldwide Market for Liquid Biopsy contains markets for the following:

  • Breast Cancer Liquid Biopsy Market (by Region - US, EUR, ASIA, ROW)
  • Colorectal Cancer Liquid Biopsy Market (by Region - US, EUR, ASIA, ROW)
  • Lung Cancer Liquid Biopsy Market (by Region - US, EUR, ASIA, ROW)
  • Ovarian Cancer Liquid Biopsy Market (by Region - US, EUR, ASIA, ROW)
  • Pancreatic Cancer Liquid Biopsy Market (by Region - US, EUR, ASIA, ROW)
  • Other Cancer Liquid Biopsy Market (by Region - US, EUR, ASIA, ROW)
  • Top Ten Companies in the Market

The currently available liquid biopsy technologies employ the analysis of various types of analytes, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles, proteins, miRNA and mRNA. Among them, ctDNA and CTCs have been the most explored technologies for commercial applications up to the present time.

Circulating tumor DNA (ctDNA) encompasses the small fragments of DNA that are believed to originate from the natural and abnormal necrosis and apoptosis processes that tumor cells undergo regularly. ctDNA fragments have the advantage of being available from different types of specimens, including urine, plasma, blood, and cerebrospinal fluid, but are rare and have a short half-life in the bloodstream, which makes their isolation and identification highly challenging. Since many cancer patients shed only very small DNA fragments into the bloodstream, ctDNA-based diagnostic technologies need to be highly sensitive in order to detect such rare events. Furthermore, ctDNA cannot provide information about protein expression, and the analysis of RNA is also difficult and limited using ctDNA. ctDNA may also result from tumor cells killed by therapeutic drugs, and does not capture information about the residual cancer that may not respond to the particular therapy or has become resistant to it.

Circulating tumor cells (CTCs) are cancer cells that are believed to detach from primary or secondary tumors and enter the bloodstream, traveling to distant organs, initiating the process of metastasis, and forming new tumors. Similarly to ctDNA, CTC-based tests could offer significant advantages compared to tissue biopsies, as they may be able to capture the heterogeneity of tumors and their genetic evolution during the disease progression and therapy. Compared to ctDNA, CTCs have a longer half-life in blood, and the analysis of viable cells could provide information about protein expression, such as PD-L1 or ER, which is not possible with ctDNA. Also, since CTCs contain intact genomic material from tumors, their analysis can reveal additional information about the biology of cancer and metastasis that is not possible to obtain from ctDNA.

This report segments market by type of cancer and corresponding regional market. For segmentation by type of analyte and type of application, see Kalorama's larger study on Liquid Biopsy Markets.

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • INTRODUCTION
  • LIQUID BIOPSY TECHNOLOGIES
  • INDUSTRY STRUCTURE
  • LIQUID BIOPSY MARKET REVENUES AND FORECAST

CHAPTER TWO: LIQUID BIOPSY TECHNOLOGIES

  • INTRODUCTION
    • Table 2-1 Comparison of Tissue and Liquid Biopsy
  • CURRENT MAJOR LIQUID BIOPSY TECHNOLOGIES
    • Table 2-2 Advantages and Limitations of Major Liquid Biopsy Technologies
  • CIRCULATING FREE DNA
  • ADVANTAGES AND LIMITATIONS OF CTDNA IN LIQUID BIOPSY
  • CURRENT CTDNA-BASED LIQUID BIOPSY TESTS
    • Table 2-3 Selected Market-Available ctDNA-based Liquid Biopsy Tests, 2017
  • Adaptive Biotechnologies
  • Biodesix
  • Epigenomics
  • Foundation Medicine
  • Genomic Health
  • Guardant Health
  • Myriad Genetics
  • Pathway Genomics
  • Personal Genome Diagnostics
  • QIAGEN
  • Roche Diagnostics
  • Sysmex-Inostics
  • Trovagene
  • CIRCULATING TUMOR CELLS (CTCS) LIQUID BIOPSY
  • CHALLENGES IN THE DEVELOPMENT OF CTCS-BASED LIQUID BIOPSY TESTS
  • CTCS-BASED LIQUID BIOPSY TESTS
    • Table 2-4 Selected Market-Available CTCs-based Liquid Biopsy Tests, 2017
  • Biocept
  • Cynvenio Biosystems
  • Epic Sciences
  • GILUPI
  • Menarini-Silicon Biosystems
  • QIAGEN
  • EXTRACELLULAR VESICLES AND OTHER LIQUID BIOPSY
  • INTRODUCTION
  • LIQUID BIOPSY TESTS BASED ON EXTRACELLULAR VESICLES
    • Table 5-1 Selected Liquid Biopsy Tests Based on Extracellular Vesicles/Other Analytes, 2017
  • Biodesix
  • Exosome Diagnostics
  • Gensignia
  • Hologic
  • MDxHealth
  • OncoCyte
  • QIAGEN
  • Vermillion
  • VolitionRx

CHAPTER THREE: LIQUID BIOPSY INDUSTRY ANALYSIS

  • INTRODUCTION
  • TIERS OF COMPETITION
    • Table 3-1 Selected Competitors in the Liquid Biopsy Market, 2017
  • COMPETITIVE FACTORS
  • SIGNIFICANT MARKET TRENDS
    • Table 3-2 Significant Trends in the Liquid Biopsy Diagnostics and Monitoring Tests Market, 2017
  • Personalized Medicine to Spur Use of Liquid Biopsy Tests in Clinical Practice
  • Increasing Global Incidence of Cancer and Life Expectancy to Increase Testing Volumes
  • New Liquid Biopsy Product Launches to Augment Market Revenues
  • Decreasing Cost of Genetic Testing to Increase Utilization of Liquid Biopsy Tests
  • Regulatory Hurdles to Limit Market Growth
  • Limitations in Third-party Payer Coverage to Restrict Test Utilization and Market Growth
  • Insufficient Demonstrated Clinical Utility to Slow Adoption by Oncologists
  • Challenges in the Integration of Liquid Biopsy Tests in Clinical Practice to Limit Market Growth

CHAPTER FOUR: CANCER LIQUID BIOPSY MARKET ANALYSIS

  • OVERALL LIQUID MARKET SNAPSHOT
    • Table 4-1 Global Liquid Biopsy Market by Type of Cancer ($ millions), 2015-2021
    • Figure 4-1 Global Liquid Biopsy Market by Type of Cancer ($ millions), 2015-2021
  • TOP TEN COMPANIES IN THE LIQUID BIOPSY MARKET
    • Table 4-2 Top Ten Companies in the Liquid Biopsy Market
  • BREAST CANCER
  • Market Snapshot
  • Revenue Forecast
    • Table 4-3 Breast Cancer Liquid Biopsy Market - by Region (US, EUR, ASIA, ROW)
  • COLORECTAL CANCER
  • Market Snapshot
  • Revenue Forecast
    • Table 4-4: Colorectal Cancer Liquid Biopsy Market - by Region (US, EUR, ASIA, ROW)
  • LUNG CANCER
  • Market Snapshot
  • Revenue Forecast
    • Table 4-5: Lung Cancer Liquid Biopsy Market - by Region (US, EUR, ASIA, ROW)
  • OVARIAN CANCER
  • Market Snapshot
  • Revenue Forecast
    • Table 4-6: Ovarian Cancer Liquid Biopsy Market - by Region (US, EUR, ASIA, ROW)
  • PROSTATE CANCER
  • Market Snapshot
  • Revenue Forecast
    • Table 4-7: Prostate Cancer Liquid Biopsy Market - by Region (US, EUR, ASIA, ROW)
  • OTHER CANCERS
  • Market Snapshot
  • Revenue Forecast
    • Table 4-8: Other Cancer Liquid Biopsy Market
Back to Top